These transcriptomic profiles suggest that CD16 and CD137 activation induces broad transcriptional reprogramming in SNK cells, which promotes the expression of genes associated with proliferation, immune signaling, and cytotoxicity and potentially contributes to the enhanced anti-tumor effects of SNK cells. The gene discussed is TNFRSF9; the disease is neoplasm.